<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Viruses</journal-id><journal-id journal-id-type="iso-abbrev">Viruses</journal-id><journal-id journal-id-type="publisher-id">viruses</journal-id><journal-title-group><journal-title>Viruses</journal-title></journal-title-group><issn pub-type="epub">1999-4915</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40007029</article-id><article-id pub-id-type="pmc">PMC11861615</article-id><article-id pub-id-type="doi">10.3390/v17020274</article-id><article-id pub-id-type="publisher-id">viruses-17-00274</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Effect of Secondary Infections on the Outcomes of Patients with Hematological Malignancies and SARS-CoV-2 Infection: Results from the HM-COV 3.0 Study</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0009-0008-1715-9532</contrib-id><name><surname>Petrucci</surname><given-names>Flavia</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role><xref rid="af1-viruses-17-00274" ref-type="aff">1</xref><xref rid="c1-viruses-17-00274" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-1077-4846</contrib-id><name><surname>Pellicano</surname><given-names>Chiara</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Software" vocab-term-identifier="https://credit.niso.org/contributor-roles/software/">Software</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><xref rid="af2-viruses-17-00274" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-5657-7373</contrib-id><name><surname>Cogliati Dezza</surname><given-names>Francesco</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization/">Visualization</role><xref rid="af1-viruses-17-00274" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Valeri</surname><given-names>Serena</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><xref rid="af1-viruses-17-00274" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Covino</surname><given-names>Sara</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><xref rid="af1-viruses-17-00274" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Iannazzo</surname><given-names>Francesco</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><xref rid="af2-viruses-17-00274" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>Infante</surname><given-names>Francesca</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><xref rid="af1-viruses-17-00274" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-2015-765X</contrib-id><name><surname>Gigante</surname><given-names>Antonietta</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization/">Visualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><xref rid="af2-viruses-17-00274" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>Sacco</surname><given-names>Federica</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><xref rid="af3-viruses-17-00274" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name><surname>Viscido</surname><given-names>Agnese</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><xref rid="af3-viruses-17-00274" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-7103-7842</contrib-id><name><surname>Iacovelli</surname><given-names>Alessandra</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization/">Visualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><xref rid="af4-viruses-17-00274" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-7417-8093</contrib-id><name><surname>Rosato</surname><given-names>Edoardo</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><xref rid="af2-viruses-17-00274" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>Palange</surname><given-names>Paolo</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><xref rid="af4-viruses-17-00274" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-1286-467X</contrib-id><name><surname>Mastroianni</surname><given-names>Claudio Maria</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role><xref rid="af1-viruses-17-00274" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-0832-7975</contrib-id><name><surname>Oliva</surname><given-names>Alessandra</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization/">Visualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role><xref rid="af1-viruses-17-00274" ref-type="aff">1</xref><xref rid="c1-viruses-17-00274" ref-type="corresp">*</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Wang</surname><given-names>Leyi</given-names></name><role>Academic Editor</role></contrib><contrib contrib-type="editor"><name><surname>Nowotny</surname><given-names>Norbert</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-viruses-17-00274"><label>1</label>Department of Public Health and Infectious Diseases, Sapienza University of Rome, Piazzale Aldo Moro 5, 00185 Rome, Italy; <email>francesco.cogliatidezza@uniroma1.it</email> (F.C.D.); <email>serena.valeri@uniroma1.it</email> (S.V.); <email>sara.covino@uniroma1.it</email> (S.C.); <email>francesca.infante@uniroma1.it</email> (F.I.); <email>claudio.mastroianni@uniroma1.it</email> (C.M.M.)</aff><aff id="af2-viruses-17-00274"><label>2</label>Department of Translational and Precision Medicine, Sapienza University of Rome, Viale Dell&#x02019;Universit&#x000e0; 37, 00185 Rome, Italy; <email>chiara.pellicano@uniroma1.it</email> (C.P.); <email>francesco.iannazzo@uniroma1.it</email> (F.I.); <email>antonietta.gigante@uniroma1.it</email> (A.G.); <email>edoardo.rosato@uniroma1.it</email> (E.R.)</aff><aff id="af3-viruses-17-00274"><label>3</label>Microbiology and Virology Laboratory, Department of Molecular Medicine, Sapienza University of Rome, Piazzale Aldo Moro 5, 00185 Rome, Italy; <email>federica.sacco@uniroma1.it</email> (F.S.); <email>agnese.viscido@uniroma1.it</email> (A.V.)</aff><aff id="af4-viruses-17-00274"><label>4</label>Department of Public Health and Infectious Diseases, Pulmonology Respiratory and Critical Care Unit, Policlinico Umberto I Hospital Rome, 00161 Rome, Italy; <email>alessandra.iacovelli@uniroma1.it</email> (A.I.); <email>paolo.palange@uniroma1.it</email> (P.P.)</aff><author-notes><corresp id="c1-viruses-17-00274"><label>*</label>Correspondence: <email>flavia.petrucci@uniroma1.it</email> (F.P.); <email>alessandra.oliva@uniroma1.it</email> (A.O.)</corresp></author-notes><pub-date pub-type="epub"><day>16</day><month>2</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>2</month><year>2025</year></pub-date><volume>17</volume><issue>2</issue><elocation-id>274</elocation-id><history><date date-type="received"><day>20</day><month>11</month><year>2024</year></date><date date-type="rev-recd"><day>28</day><month>12</month><year>2024</year></date><date date-type="accepted"><day>14</day><month>2</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; 2025 by the authors.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>Patients with hematological malignancies (HMs) are at higher risk of severe COVID-19 and secondary infections, which further complicate their outcomes. This study evaluated the impact of secondary infections (SIs) on mortality in hospitalized HM patients with SARS-CoV-2 infection and identified risk factors associated with SIs. We included 217 patients with HMs and COVID-19 admitted to a tertiary hospital in Rome, from April 2020 to September 2022. SIs occurred in 44.2% of patients, with bloodstream infections (42.7%) and respiratory infections (30.5%) being most frequent; among the latter, COVID-19-associated pulmonary aspergillosis (CAPA) was observed in 41.4% of cases. Viral reactivations, predominantly CMV, occurred in 9.2% of patients. The overall mortality rate was 29%, with higher mortality observed in patients with SIs (47.4% vs. 14.7%, <italic toggle="yes">p</italic> &#x0003c; 0.01). Risk factors for SIs included severe COVID-19 (OR = 2.957, <italic toggle="yes">p</italic> &#x0003c; 0.05) and prolonged hospitalization (OR = 1.095, <italic toggle="yes">p</italic> &#x0003c; 0.001). Severe COVID-19 (OR = 8.229, <italic toggle="yes">p</italic> &#x0003c; 0.001), intensive care unit (ICU) admission (OR = 15.232, <italic toggle="yes">p</italic> &#x0003c; 0.001), chronic steroid therapy (OR = 2.803, <italic toggle="yes">p</italic> &#x0003c; 0.05), SIs (OR = 2.892, <italic toggle="yes">p</italic> &#x0003c; 0.05), and viral reactivation (OR = 6.269, <italic toggle="yes">p</italic> &#x0003c; 0.01) were independent predictors of mortality. SIs and viral reactivations are common in patients with HMs and SARS-CoV-2 infection and significantly increase mortality, highlighting the need for timely management and preventive strategies in this vulnerable population.</p></abstract><kwd-group><kwd>SARS-CoV-2</kwd><kwd>COVID-19</kwd><kwd>hematological malignancies</kwd><kwd>secondary infections</kwd><kwd>viral reactivation</kwd><kwd>COVID-19-associated pulmonary aspergillosis (CAPA)</kwd><kwd>mortality</kwd></kwd-group><funding-group><award-group><funding-source>Sapienza University of Rome under the project &#x02018;Progetti per Avvio alla Ricerca&#x02014;Tipo 1, 2023&#x02019;</funding-source><award-id>AR123188B452BF8A</award-id></award-group><funding-statement>This work was partially supported by Sapienza University of Rome under the project &#x02018;Progetti per Avvio alla Ricerca&#x02014;Tipo 1, 2023&#x02019; (Grant No. AR123188B452BF8A).</funding-statement></funding-group></article-meta></front><body><sec sec-type="intro" id="sec1-viruses-17-00274"><title>1. Introduction</title><p>Since the onset of the COVID-19 pandemic, more than seven million deaths have been reported worldwide, with approximately 200,000 in Italy [<xref rid="B1-viruses-17-00274" ref-type="bibr">1</xref>]. Patients with hematological malignancies (HMs) are at a higher risk of severe SARS-CoV-2 infection and tend to experience worse outcomes [<xref rid="B2-viruses-17-00274" ref-type="bibr">2</xref>,<xref rid="B3-viruses-17-00274" ref-type="bibr">3</xref>]. Mortality rates in this population range from 10% to 40%, and these patients are more likely to require admission to Intensive Care Units (ICUs), experience prolonged viral shedding, and undergo extended hospitalization [<xref rid="B4-viruses-17-00274" ref-type="bibr">4</xref>,<xref rid="B5-viruses-17-00274" ref-type="bibr">5</xref>,<xref rid="B6-viruses-17-00274" ref-type="bibr">6</xref>]. Additionally, this group appears to be particularly prone to the development of secondary infections (SIs), with epidemiological studies reporting a prevalence ranging from 7.7% in an Italian cohort [<xref rid="B7-viruses-17-00274" ref-type="bibr">7</xref>] to approximately 19% in a multicenter international study [<xref rid="B8-viruses-17-00274" ref-type="bibr">8</xref>]. These infections further complicate their clinical course, especially when multidrug-resistant (MDR) organisms are involved [<xref rid="B7-viruses-17-00274" ref-type="bibr">7</xref>,<xref rid="B8-viruses-17-00274" ref-type="bibr">8</xref>]. Among secondary infections, particular attention has been drawn to COVID-19-associated pulmonary aspergillosis (CAPA), a complication increasingly recognized in immunocompromised patients and associated with elevated morbidity and mortality rates in those with severe SARS-CoV-2 infection [<xref rid="B9-viruses-17-00274" ref-type="bibr">9</xref>,<xref rid="B10-viruses-17-00274" ref-type="bibr">10</xref>].</p><p>This predisposition to superinfections is consistent with what has been observed in other viral diseases, such as influenza, where secondary bacterial infections contribute significantly to morbidity and mortality [<xref rid="B11-viruses-17-00274" ref-type="bibr">11</xref>,<xref rid="B12-viruses-17-00274" ref-type="bibr">12</xref>]. Understanding the impact of secondary infections on patients with HMs and COVID-19 is crucial for improving their management and outcomes.</p><p>The study aims to assess the impact of secondary infections (SIs) on the outcomes of hospitalized patients with HMs and SARS-CoV-2 infection. Specifically, it will examine mortality rates, the need for admission to ICUs and the duration of the hospital stay. As a secondary objective, the study will also seek to identify the factors that predispose these patients to the development of SIs.</p></sec><sec id="sec2-viruses-17-00274"><title>2. Materials and Methods</title><sec id="sec2dot1-viruses-17-00274"><title>2.1. Study Population</title><p>This retrospective, single-center study was conducted on patients with HMs and SARS-CoV-2 infection, who were admitted to a tertiary hospital in Rome between April 2020 and September 2022.</p><p>Inclusion criteria for the study were: (i) age over 18 years, (ii) confirmed diagnosis of SARS-CoV-2 infection, (iii) diagnosis of a hematological malignancy, and (iv) hospitalization during the study period. Patients under the age of 18 or with non-malignant hematologic diseases were excluded from the analysis.</p><p>The cohort was subsequently divided into two groups: those who developed SIs (SI+) and those who did not (SI-), to compare outcomes.</p><p>For the purposes of this study, we considered all patients enrolled from the end of January 2022 onward as being affected by the Omicron variant, as Omicron became the dominant strain in Italy by that time, accounting for 99% of cases [<xref rid="B13-viruses-17-00274" ref-type="bibr">13</xref>]. For each subject, laboratory and clinical data at hospital admission, as well as treatment data and SARS-CoV-2 RNA time of detection, were collected and recorded anonymously in an electronic database.</p></sec><sec id="sec2dot2-viruses-17-00274"><title>2.2. Definitions</title><p>To confirm SARS-CoV-2 infection, nasopharyngeal swab samples were collected and analyzed by means of molecular (RealStar SARS-CoV2 RT-PCR, Altona Diagnostics, Hamburg, Germany) or antigenic (Liaison, Diasorin, Vercelli, Italy) testings, as appropriate and according to the local protocols. Severity of the SARS-CoV-2 infection was defined according to the WHO classification available at the time of enrolment [<xref rid="B14-viruses-17-00274" ref-type="bibr">14</xref>]. The status of the hematological malignancy was defined as remission, refractory/relapsing disease, or yet to be defined, according to the guidelines of the European Society for Medical Oncology [<xref rid="B15-viruses-17-00274" ref-type="bibr">15</xref>]. Patients with either a new diagnosis or refractory/relapsing disease were categorized as having active malignancy. Active treatment included receipt of chemotherapy or immunotherapy, or both, in the previous 90 days. Immunotherapy included receipt of monoclonal antibodies (rituximab, daratumumab, and obinutuzumab) and tyrosine kinase inhibitors (imatinib, ibrutinib, ruxolitinib, and venetoclax). The use of corticosteroids within the previous 30 days included therapy with prednisone or its equivalent at a dose &#x0003e; 0.5 mg/kg/day for at least 1 month.</p><p>Secondary infection was defined as any infection that developed 48 h after hospital admission, primarily focusing on hospital-acquired infections. Their diagnosis was obtained through microbiological samples collected according to the suspected primary infection site (e.g., blood cultures, urine cultures, sputum, tracheobronchial aspirates, urine, abscesses). Infections were defined according to the CDC/NHSN criteria [<xref rid="B16-viruses-17-00274" ref-type="bibr">16</xref>]. Hospital-acquired/ventilator-associated pneumonia (HAP/VAP) was defined in accordance with the CDC/NHSN surveillance definition of healthcare-associated infection for pneumonia with specific criteria [<xref rid="B17-viruses-17-00274" ref-type="bibr">17</xref>]. VAP was defined as pneumonia in patients who had a device to assist or control respiration continuously through a tracheostomy or by endotracheal intubation within the 48 h period before the onset of infection.</p><p>CAPA was defined according to the recently proposed definitions [<xref rid="B18-viruses-17-00274" ref-type="bibr">18</xref>] as well as the practice guidelines [<xref rid="B19-viruses-17-00274" ref-type="bibr">19</xref>] using a combination of clinical, radiological, and mycological features of the disease. In case of doubt, a panel discussion was conducted.</p></sec><sec id="sec2dot3-viruses-17-00274"><title>2.3. Microbiological Analyses</title><p>Standard microbiological procedures were performed at hospital admission and/or during hospitalization as requested by the attending physicians, in order to investigate bacterial, viral, and fungal pathogens in the blood, normally sterile fluids, sputum, and other samples, as appropriate. According to routine Hospitals&#x02019; Microbiology Laboratory protocol, a bacterial pellet obtained from positive blood cultures was used for bacterial identification by the Matrix-Assisted Laser Desorption Ionization&#x02013;Time Of Flight Mass Spectrometry (MALDI-TOF MS) system (Bruker Daltonik GmbH, Bremen, Germany). Isolated colonies from other biological samples were identified by the MALDI-TOF MS system (Bruker Daltonik GmbH, Bremen, Germany). Antimicrobial susceptibility testing was performed with the Vitek 2 automated system (bioM&#x000e9;rieux, Marcy l&#x02019;Etoile, France) and Microscan Walkaway (Beckman and Coulter, Brea, CA, USA) system, as appropriate. As for local protocol, screening for MDR bacteria (i.e methicillin-resistant <italic toggle="yes">Staphylococcus aureus</italic> (MRSA) or carbapenem resistant gram-negative bacilli [<xref rid="B20-viruses-17-00274" ref-type="bibr">20</xref>]) colonization was systematically performed by means of a rectal/nasal swab or lower respiratory samples, as appropriate.</p><p>With regard to CAPA diagnosis, galactomannan (GM), and fungal culture were performed on respiratory samples. Fungal cultures were incubated for 7 days at 30 &#x000b0;C on Sabouraud selective media, whereas a GM test in serum, bronchoalveolar lavage (BAL), and tracheobronchial aspirate (TBA) was performed according to the manufacturer&#x02019;s instructions (Platelia Aspergillus EIA, Bio-Rad, Milan, Italy).</p><p>Viral reactivation was considered when DNA quantification was higher than the limit of detection, supported by clinical signs of infections [<xref rid="B21-viruses-17-00274" ref-type="bibr">21</xref>].</p><p>In the case of suspected SIs and/or CAPA, the clinical approach was managed together with a dedicated ID physician. In the case of suspected secondary infections, all patients received promptly empiric antibiotic therapy, whereas definitive antibiotic therapy was based on the results of cultures. When feasible, a lung CT scan was performed to detect lesions compatible with invasive pulmonary aspergillosis (IPA) and was analyzed with a dedicated pneumologist and radiologist.</p></sec><sec id="sec2dot4-viruses-17-00274"><title>2.4. Statistical Analyses</title><p>Categorical variables were described through absolute frequencies and percentages; quantitative variables were reported through mean and SD or median with an interquartile range, depending on the normal or non-normal distribution of the data, respectively. The coefficient of kurtosis and skewness was used to evaluate normal or non-normal distribution of data. Differences between qualitative variables were analyzed by means of Chi-square or Fischer&#x02019;s exact tests, as appropriate, while differences between quantitative variables were assessed by means of t-Student or Mann&#x02013;Whitney U tests, as appropriate. Univariable analysis was used to identify risk factors and predictors for all-cause in-hospital mortality. Baseline predictors possibly associated with the outcome at univariable comparison and variables considered clinically significant were considered for multivariable logistic regression analysis. Multivariable stepwise logistic regression analysis with an Odds Ratio (OR) and 95% confidence intervals (CIs) was applied to evaluate the association of the following independent variables: age, female sex, Omicron variant, severe COVID-19, chronic steroid therapy, HM remission, eGFR &#x02264; 45 mL/min, CRP/albumin, admission to ICU, secondary infections, viral reactivation for in-hospital mortality and age, female sex, severe COVID-19, chronic steroid therapy, neutropenia, CRP/albumin, admission to ICU, length of stay for secondary infections development. Variables&#x02019; collinearity and interaction were also checked in the final model. <italic toggle="yes">p</italic> values &#x0003c; 0.05 were considered significant. All statistical analyses were performed using STATA<sup>TM</sup> software, v. 17 (StataCorp, College Station, TX, USA) and Graphpad Prism<sup>TM</sup> v.8, charts using Microsoft Office<sup>TM</sup> v. 16 and Graphpad Prism<sup>TM</sup> v. 8.</p></sec><sec id="sec2dot5-viruses-17-00274"><title>2.5. Ethics</title><p>The study was conducted in accordance with the principles of the Declaration of Helsinki. The protocol was approved by the local Ethics Committee (ID Prot. 109/2020). The clinical and diagnostic management of the patients had already been carried out according to normal clinical practice. Informed consent was waived due to the retrospective nature of the research.</p></sec></sec><sec sec-type="results" id="sec3-viruses-17-00274"><title>3. Results</title><sec id="sec3dot1-viruses-17-00274"><title>3.1. General Characteristics and Clinical Outcomes</title><p>The study included 217 patients with a median age of 69 years [IQR 57&#x02013;77], of whom 61.7% were male. Omicron infection was present in 51.1% of patients and 64% had been previously vaccinated. Asymptomatic COVID-19 was seen in 18.4% of cases, while 21.2% experienced severe illness. Renal function (eGFR) had a median of 79.7 mL/min, with 15.7% showing eGFR &#x02264; 45 mL/min. Regarding hematological conditions, the most common were non-Hodgkin lymphoma (38.7%) and chronic lymphocytic leukemia (10.6%). Hematological disease was in remission for 44.7% of patients, while 34.6% were on chronic steroid therapy and 54.4% were on active treatment. ICU admission occurred in 14.3% of patients and the overall mortality rate was 29%; the median hospital stay was 16 days [IQR 9&#x02013;30]. Other demographic and clinical features of patients are shown in <xref rid="viruses-17-00274-t001" ref-type="table">Table 1</xref>. </p></sec><sec id="sec3dot2-viruses-17-00274"><title>3.2. Secondary Infections and Viral Reactivations</title><p>At least one SI was observed in 44.2% of patients, with the most common types being BSI (42.7%) and respiratory tract infections (30.5%). Among respiratory tract infections, HAP/VAP accounted for 58.6%, while CAPA represented 41.4%. These were followed by urinary tract infections, intra-abdominal and other less common infections, including two cases of skin and soft tissue infection, one case of otomastoiditis caused by <italic toggle="yes">Staphylococcus aureus</italic> and one case of mucormycosis. Overall, isolated microorganisms were Gram-positive in 39.2% of cases, Gram-negative in 52.3% and fungi in 8.4%. Specifically, the most frequently isolated pathogens included <italic toggle="yes">Escherichia coli</italic> (13.1%), <italic toggle="yes">Klebsiella pneumoniae</italic> (11.2%), <italic toggle="yes">Acinetobacter baumannii</italic> (11.2%), coagulase-negative <italic toggle="yes">Staphylococci</italic> (10.3%), and <italic toggle="yes">Enterococcus faecium</italic> (8.4%), regardless of the infection type.</p><p>When considering specific infection types, we observed the following distribution: BSI was caused mainly by <italic toggle="yes">E. faecium</italic> (19%), followed by <italic toggle="yes">K. pneumoniae</italic>, <italic toggle="yes">E. coli</italic>, <italic toggle="yes">Staphylococcus epidermidis</italic>, and <italic toggle="yes">Staphylococcus haemolyticus</italic> (14.3% each) and <italic toggle="yes">A. baumannii</italic> (12%). With regard to pneumonia, 18,6% were sustained by <italic toggle="yes">A. baumannii</italic> and 14% by <italic toggle="yes">K. pneumoniae</italic>. In 23.2% of pneumonia cases, the pathogen was not identified. Among the other identified pathogens, <italic toggle="yes">Streptococccus pneumoniae</italic> accounted for 7% and <italic toggle="yes">E. coli</italic> and <italic toggle="yes">Enterobacter cloacae</italic> for 4.6% each. Urinary tract infections were caused mainly by <italic toggle="yes">E. coli</italic> (13.3%), <italic toggle="yes">Enterococcus faecalis</italic> (13.3%), <italic toggle="yes">Proteus mirabilis</italic> (13.3%), and <italic toggle="yes">Pseudomonas aeruginosa</italic> (13.3%). Viral reactivation occurred in 9.2% of cases, mostly caused by CMV reactivation (<xref rid="viruses-17-00274-t001" ref-type="table">Table 1</xref>).</p><p>During hospitalization, 18.9% of patients developed colonization by a multidrug-resistant (MDR) microorganism.</p></sec><sec id="sec3dot3-viruses-17-00274"><title>3.3. Comparison Between Survivors and Non-Survivors</title><p>Dividing the patients into two groups based on survival (n = 154, 71%) and death (n = 63, 29%) (<xref rid="viruses-17-00274-t002" ref-type="table">Table 2</xref>), several key differences were observed. The median age of patients and male gender distribution were not statistically significant (70 vs. 69 years, <italic toggle="yes">p</italic> &#x0003e; 0.05 and 59.1% vs. 68.2%, <italic toggle="yes">p</italic>&#x0003e; 0.05). The median eGFR was lower in non-survivor patients (75.3 mL/min) than in those who survived (81.6 mL/min, <italic toggle="yes">p</italic> &#x0003e; 0.05), although not statistically different. Furthermore, CRP/albumin and D-Dimer levels were significantly elevated in deceased patients (2 vs. 0.7, <italic toggle="yes">p</italic> &#x0003c; 0.001; 1162.5 ng/mL vs. 729.5 ng/mL, <italic toggle="yes">p</italic> &#x0003c; 0.001). A lower percentage of deceased patients (38.1%) had the Omicron variant compared to 56.5% of survivors (<italic toggle="yes">p</italic> &#x0003c; 0.01); instead, the vaccination rate did not show a statistically significant difference between the two groups (57.1% vs. 67.3%, <italic toggle="yes">p</italic> &#x0003e; 0.05). Severe COVID-19 disease was significantly more prevalent among deceased patients (46%) compared to only 11% of survivors (<italic toggle="yes">p</italic> &#x0003c; 0.001). Chronic steroid therapy was more common in the non-survivor group (50%) compared to the survivor group (28.8%, <italic toggle="yes">p</italic> &#x0003c; 0.01). Additionally, 41.3% of those who died were admitted to the ICU, compared to only 3.2% of survivors (<italic toggle="yes">p</italic> &#x0003c; 0.001). Patients who died had a longer median hospital stay of 20 days, in contrast to 16 days for survivors; however, this difference was not statistically significant (<italic toggle="yes">p</italic> &#x0003e; 0.05). The prevalence of MDR colonization was significantly higher among deceased patients (36.5%) compared to survivors (11.7%, <italic toggle="yes">p</italic> &#x0003c; 0.001) and, similarly, non-survivors had a higher percentage of SIs (71.4% vs. 32.4%, <italic toggle="yes">p</italic> &#x0003c; 0.001) and viral reactivations (19% vs. 5.2%, <italic toggle="yes">p</italic> &#x0003c; 0.001) (<xref rid="viruses-17-00274-t002" ref-type="table">Table 2</xref>).</p><p>In the multivariable logistic regression analysis, mortality was significantly associated with severe SARS-CoV-2 disease [OR = 8.229 (95% CI: 2.913&#x02013;23.249); <italic toggle="yes">p</italic> &#x0003c; 0.001], chronic steroid therapy [OR = 2.803 (95% CI: 1.003&#x02013;7.830); <italic toggle="yes">p</italic> &#x0003c; 0.05], admission to the ICU [OR = 15.232 (95% CI: 3.838&#x02013;60.452); <italic toggle="yes">p</italic> &#x0003c; 0.001], eGFR &#x02264; 45 mL/min [OR = 11.338 (95% CI: 3.273&#x02013;39.278); <italic toggle="yes">p</italic> &#x0003c; 0.001], secondary infections [OR = 2.892 (95% CI: 1.093&#x02013;7.649); <italic toggle="yes">p</italic> &#x0003c; 0.05], and viral reactivations [OR = 6.269 (95% CI: 1.734&#x02013;55.669); <italic toggle="yes">p</italic> &#x0003c; 0.01] (<xref rid="viruses-17-00274-t003" ref-type="table">Table 3</xref>).</p></sec><sec id="sec3dot4-viruses-17-00274"><title>3.4. Comparison Between Patients With and Without Secondary Infections</title><p>Overall, a total of 96 (44.2%) patients developed SIs. Severe COVID-19 disease was more common among patients with SIs (30.2%) than in those without (14%, <italic toggle="yes">p</italic> &#x0003c; 0.01). Patients with SIs were more frequently on chronic steroid therapy (48.4% vs. 24.2%, <italic toggle="yes">p</italic> &#x0003c; 0.001) and were more often neutropenic (15.6% vs. 6.7%, <italic toggle="yes">p</italic> &#x0003c; 0.05). CRP/albumin levels were significantly higher in patients with secondary infections (1.7) compared to those without (0.7, <italic toggle="yes">p</italic> &#x0003c; 0.001). Additionally, 71% of those who developed a SI were admitted to the ICU, compared to only 29% of those who did not (<italic toggle="yes">p</italic> &#x0003c; 0.001) and MDR colonization was markedly more frequent in patients with a SI (35.4%) than in those without (5.8%, <italic toggle="yes">p</italic> &#x0003c; 0.001). The mortality rate was significantly higher among patients with SIs (47.4%) compared to those without (14.7%, <italic toggle="yes">p</italic> &#x0003c; 0.01). Likewise, patients with SIs had a significantly longer median hospital stay of 30 days, compared to just 11 days for those without SIs (<italic toggle="yes">p</italic> &#x0003c; 0.001) (<xref rid="viruses-17-00274-t002" ref-type="table">Table 2</xref>).</p><p>Examining the risk factors for SIs, the multivariable logistic regression analysis revealed that secondary infections development was significantly associated with severe SARS-CoV-2 disease [OR = 2.957 (95% CI: 1.258&#x02013;6.950); <italic toggle="yes">p</italic> &#x0003c; 0.05], length of stay [OR = 1.095 (95% CI: 1.056&#x02013;1.136); <italic toggle="yes">p</italic> &#x0003c; 0.001], chronic steroid therapy [OR = 2.902 (95% CI: 1.421&#x02013;5.925); <italic toggle="yes">p</italic> &#x0003c; 0.01] and neutropenia [OR = 3.280 (95% CI: 1.067&#x02013;10.087); <italic toggle="yes">p</italic> &#x0003c; 0.05] (<xref rid="viruses-17-00274-t003" ref-type="table">Table 3</xref>).</p></sec></sec><sec sec-type="discussion" id="sec4-viruses-17-00274"><title>4. Discussion</title><p>The present study describes the clinical characteristics and outcomes of hospitalized patients with HMs and SARS-CoV-2 infection, along with the evaluation of predictors of SIs development and the impact of SIs on mortality. We found that SIs were an independent risk factor for mortality in this high-risk population and that the severity of SARS-CoV-2 disease as well as immunosuppression (expressed by chronic steroid therapy and neutropenia) were predictors of SIs.</p><p>It is well known that the HM population presents a higher rate of complications and worse outcome and specific kinetics of respiratory worsening [<xref rid="B2-viruses-17-00274" ref-type="bibr">2</xref>,<xref rid="B3-viruses-17-00274" ref-type="bibr">3</xref>,<xref rid="B4-viruses-17-00274" ref-type="bibr">4</xref>,<xref rid="B5-viruses-17-00274" ref-type="bibr">5</xref>,<xref rid="B6-viruses-17-00274" ref-type="bibr">6</xref>], and this was confirmed by the high mortality rate found also in the present study (29%). Drivers of worse outcome in the present study were not only the severity of the SARS CoV2 infection or a chronic steroid therapy but also SIs (including CAPA) and viral reactivation. Secondary infections in COVID-19 patients are reported in the literature with a prevalence of around 22% [<xref rid="B22-viruses-17-00274" ref-type="bibr">22</xref>,<xref rid="B23-viruses-17-00274" ref-type="bibr">23</xref>], especially in ICUs, where they represented an independent predictor of mortality [<xref rid="B24-viruses-17-00274" ref-type="bibr">24</xref>].</p><p>So far, limited data are available about the impact of SIs in HM patients hospitalized for COVID-19 disease; our study reported a 44.2% rate of secondary infections, higher than in similar studies, where rates vary between 7% and 19% [<xref rid="B7-viruses-17-00274" ref-type="bibr">7</xref>,<xref rid="B8-viruses-17-00274" ref-type="bibr">8</xref>].</p><p>According to the literature, we observed a numerically lower mortality rate in patients infected with Omicron VOCs (38.1% deceased patients vs. 56.5% survived, <italic toggle="yes">p</italic> &#x0003c; 0.01), which, however, did not result an independent predictor of mortality. Although in the general population, the Omicron variant is associated with a lower mortality rate [<xref rid="B25-viruses-17-00274" ref-type="bibr">25</xref>,<xref rid="B26-viruses-17-00274" ref-type="bibr">26</xref>], studies in hematology patients have shown only a slight reduction in mortality compared to previous VOCs. Unlike immunocompetent individuals, infection with Omicron in HM patients remains associated with significant mortality among hospitalized individuals [<xref rid="B27-viruses-17-00274" ref-type="bibr">27</xref>].</p><p>The occurrence of secondary infections in 44.2% of patients further highlights the challenges posed by compromised immune function in individuals with hematological diseases. Bloodstream infections were the most frequent secondary infections, with <italic toggle="yes">E. faecium</italic>, <italic toggle="yes">E. coli</italic>, <italic toggle="yes">S. epidermidis</italic>, and <italic toggle="yes">A. baumannii</italic> being the predominant causative agents. BSI had a similar distribution of Gram-negative and Gram-positive organisms, and the specific type of isolates did not appear to influence survival. Gram-positive bacteria may be partially explained by the frequent use of central venous catheters in critically ill and frail patients, while the high prevalence of Gram-negative bacteria is consistent with recent epidemiological data reported in HM patients [<xref rid="B28-viruses-17-00274" ref-type="bibr">28</xref>]. Pneumonia and urinary tract infections also featured prominently, while intra-abdominal infections were primarily attributed to <italic toggle="yes">Clostridium difficile</italic>.</p><p>We found that CAPA occurred in 5.52% of patients and represented 41.4% of the respiratory infection in our cohort. There is a growing interest in coronavirus-associated pulmonary aspergillosis (CAPA) and its association with critical illness [<xref rid="B9-viruses-17-00274" ref-type="bibr">9</xref>,<xref rid="B29-viruses-17-00274" ref-type="bibr">29</xref>]. The prevalence of CAPA in our study (5.52%) falls within the range widely reported in the literature (5&#x02013;30%) [<xref rid="B10-viruses-17-00274" ref-type="bibr">10</xref>]. However, it is interesting to note that the variation between studies may reflect differences in diagnostic criteria, patient characteristics (e.g., the underlying hematological disease) or limitations in diagnostic investigations during the pandemic. Specifically, our incidence may have been influenced by difficulties in performing invasive diagnostic procedures, such as bronchoscopy, due to COVID-19 containment measures and/or patients&#x02019; clinical conditions. However, although data about HM patients are few, CAPA represents a significant complication and risk factor for mortality even in immunocompetent patients [<xref rid="B29-viruses-17-00274" ref-type="bibr">29</xref>]. Therefore, recognizing CAPA symptoms and raising a diagnostic suspicion can be challenging, but it is necessary to prevent fatal outcomes, especially in high-risk patients, such as those with an HM, allowing for the prompt initiation of prophylaxis, if necessary.</p><p>One interesting aspect of the study is the finding that viral reactivation, which affected 9.2% of patients and, as expected, was predominantly linked to CMV reactivation, was a predictor itself of mortality. While the literature reports data on viral reactivation in critically ill COVID-19 patients [<xref rid="B30-viruses-17-00274" ref-type="bibr">30</xref>,<xref rid="B31-viruses-17-00274" ref-type="bibr">31</xref>], few studies have investigated the impact of these reactivations on patient mortality, particularly in those with hematologic malignancies. This highlights the complex interplay between immune suppression, underlying hematological diseases, and viral reactivations, necessitating vigilant monitoring and tailored preventive strategies since there is a direct impact on mortality. </p><p>As expected, patients with SIs exhibited a significantly prolonged median length of stay compared to those without (30 vs. 11 days), underscoring the burden of secondary infections on healthcare resources and patient well-being.</p><p>In our cohort, we found an overall mortality of 29%: the higher mortality rate observed in our study, compared to other reports, could be attributed to several factors. All patients included in our cohort required hospitalization, which likely contributed to the overall high mortality. Additionally, the median age of our patients was relatively high, which may have further increased the risk of adverse outcomes. More than half of the patients were not infected with the Omicron variant, and many were undergoing active treatment for their underlying hematological malignancy, which could have made them more vulnerable to severe COVID-19 and associated complications, such as SIs, which we found to be independently associated with mortality.</p><p>SIs significantly contribute to mortality in HM patients through various mechanisms. Immune suppression, either due to underlying malignancies, SARS-CoV-2 infection itself or treatments received for the underlying malignancy, predisposes these patients to a higher risk of bacterial, fungal, and viral infections. Once established, SIs exacerbate systemic inflammation and immune dysregulation, possibly leading to septic syndrome and multiorgan failure, both of which are major causes of mortality in this population. Additionally, bloodstream infections, which were among the most frequent SIs in our cohort, are known to have particularly high mortality rates in critically ill patients due to their rapid progression and difficulty of management. Similarly, viral reactivation, particularly CMV, may act as a predictor of mortality by further compromising the immune response. CMV reactivation is associated with a pro-inflammatory state, cytokine storm and end-organ damage, which can exacerbate the already fragile clinical condition of HM patients. The interplay between viral reactivation and immune suppression creates a vicious cycle, increasing the likelihood of co-infections and further patients&#x02019; deterioration.</p><p>This study inevitably presents some limitations, primarily due to its retrospective design and single-center nature. The small number of patients did not allow for stratification by hematological pathology or type of SIs, and, consequently, the potential impact of these differences on disease outcomes remains unclear. Furthermore, the inclusion of patients from the early pandemic phase, when therapeutic guidelines were not yet fully established and broad-spectrum antibiotics were often inappropriately used, may have influenced the incidence of SIs observed in our cohort. In line with this, we included patients from different pandemic phases (e.g., the first wave and the Omicron phase), potentially introducing additional treatment strategy variability. To mitigate these limitations in future research, we plan to conduct larger, multicenter studies with improved data collection and more comprehensive patient stratification. Addressing these biases and expanding the scope of the research will enable a more accurate understanding of the factors that contribute to poor outcomes in HM patients with SARS-CoV-2 infection. Nevertheless, our findings reinforce the fragility of this patient population, which remains highly susceptible to SIs, that further worsen the prognosis. Additional studies are needed to better identify risk factors and refine strategies to prevent unfavorable outcomes in this vulnerable group.</p></sec><sec sec-type="conclusions" id="sec5-viruses-17-00274"><title>5. Conclusions</title><p>In conclusion, this study sheds light on the complex clinical landscape faced by inpatients with hematological diseases, particularly in the context of SARS-CoV2 infection. The high prevalence of secondary infections including viral reactivation and their association with increased mortality highlights the need for tailored management approaches that consider the unique challenges posed by both the underlying hematological conditions and the infectious agents. By identifying key risk factors and their implications, this research paves the way for improved patient care and informs future interventions aimed at reducing the morbidity and mortality in this vulnerable population. Further studies are warranted to explore specific preventive and therapeutic strategies targeting secondary infections in this cohort.</p></sec></body><back><ack><title>Acknowledgments</title><p>The authors thank all the physicians devoted to the cure of patients with hematological malignancies and COVID-19 hospitalized at Azienda Policlinico Umberto I, Sapienza University of Rome. The authors also thank all the nursing staff for their assistance with COVID-19 patients.</p></ack><fn-group><fn><p><bold>Disclaimer/Publisher&#x02019;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><notes><title>Author Contributions</title><p>Conceptualization, A.O. and F.P.; methodology, C.P.; software, C.P.; validation, A.O., C.M.M. and A.G.; formal analysis, C.P.; investigation, F.P., S.V. and F.C.D.; resources, A.O.; data curation, F.P., S.V., S.C., F.I. (Francesca Infante), F.I. (Francesco Iannazzo), F.S., A.V. and F.C.D.; writing&#x02014;original draft preparation, F.P. and A.O.; writing&#x02014;review and editing, F.P. and A.O.; visualization, F.C.D., A.O., A.I. and A.G.; supervision, A.G., A.I., P.P., E.R., C.M.M. and A.O.; project administration, A.O. and C.M.M.; funding acquisition, F.P. and A.O. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>The study was conducted in accordance with the principles of the Declaration of Helsinki. The protocol was approved by the local Ethics Committee (ID Prot. 109/2020). The clinical and diagnostic management of the patients had already been carried out according to normal clinical practice.</p></notes><notes><title>Informed Consent Statement</title><p>Informed consent was waived due to the retrospective nature of the research.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>All data relevant to the study are included in the article.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></notes><ref-list><title>References</title><ref id="B1-viruses-17-00274"><label>1.</label><element-citation publication-type="webpage"><article-title>WHO COVID-19 Dashboards</article-title><comment>Available online: <ext-link xlink:href="https://data.who.int/dashboards/covid19/deaths" ext-link-type="uri">https://data.who.int/dashboards/covid19/deaths</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-09-01">(accessed on 1 September 2024)</date-in-citation></element-citation></ref><ref id="B2-viruses-17-00274"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>El-Sharkawi</surname><given-names>D.</given-names></name>
<name><surname>Iyengar</surname><given-names>S.</given-names></name>
</person-group><article-title>Haematological cancers and the risk of severe COVID-19: Exploration and critical evaluation of the evidence to date</article-title><source>Br. J. Haematol.</source><year>2020</year><volume>190</volume><fpage>336</fpage><lpage>345</lpage><pub-id pub-id-type="doi">10.1111/bjh.16956</pub-id><pub-id pub-id-type="pmid">32559308</pub-id>
</element-citation></ref><ref id="B3-viruses-17-00274"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pagano</surname><given-names>L.</given-names></name>
<name><surname>Salmanton-Garc&#x000ed;a</surname><given-names>J.</given-names></name>
<name><surname>Marchesi</surname><given-names>F.</given-names></name>
<name><surname>Busca</surname><given-names>A.</given-names></name>
<name><surname>Corradini</surname><given-names>P.</given-names></name>
<name><surname>Hoenigl</surname><given-names>M.</given-names></name>
<name><surname>Klimko</surname><given-names>N.</given-names></name>
<name><surname>Koehler</surname><given-names>P.</given-names></name>
<name><surname>Pagliuca</surname><given-names>A.</given-names></name>
<name><surname>Passamonti</surname><given-names>F.</given-names></name>
<etal/>
</person-group><article-title>COVID-19 infection in adult patients with hematological malignancies: A European Hematology Association Survey (EPICOVIDEHA)</article-title><source>J. Hematol. Oncol.</source><year>2021</year><volume>14</volume><fpage>168</fpage><pub-id pub-id-type="doi">10.1186/s13045-021-01177-0</pub-id><pub-id pub-id-type="pmid">34649563</pub-id>
</element-citation></ref><ref id="B4-viruses-17-00274"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Oliva</surname><given-names>A.</given-names></name>
<name><surname>Cogliati Dezza</surname><given-names>F.</given-names></name>
<name><surname>Petrucci</surname><given-names>F.</given-names></name>
<name><surname>Romani</surname><given-names>F.E.</given-names></name>
<name><surname>Morviducci</surname><given-names>M.</given-names></name>
<name><surname>Mirabelli</surname><given-names>F.M.</given-names></name>
<name><surname>Cancelli</surname><given-names>F.</given-names></name>
<name><surname>Valeriani</surname><given-names>E.</given-names></name>
<name><surname>Marcelli</surname><given-names>G.</given-names></name>
<name><surname>Pugliese</surname><given-names>F.</given-names></name>
<etal/>
</person-group><article-title>Outcome of COVID-19 patients with haematological malignancies after the introduction of vaccination and monoclonal antibodies: Results from the HM-COV 2.0 study</article-title><source>Clin. Exp. Med.</source><year>2023</year><volume>23</volume><fpage>2275</fpage><lpage>2285</lpage><pub-id pub-id-type="doi">10.1007/s10238-023-01027-y</pub-id><pub-id pub-id-type="pmid">36867292</pub-id>
</element-citation></ref><ref id="B5-viruses-17-00274"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Oliva</surname><given-names>A.</given-names></name>
<name><surname>Curtolo</surname><given-names>A.</given-names></name>
<name><surname>Volpicelli</surname><given-names>L.</given-names></name>
<name><surname>Cancelli</surname><given-names>F.</given-names></name>
<name><surname>Borrazzo</surname><given-names>C.</given-names></name>
<name><surname>Dezza</surname><given-names>F.C.</given-names></name>
<name><surname>Marcelli</surname><given-names>G.</given-names></name>
<name><surname>Gavaruzzi</surname><given-names>F.</given-names></name>
<name><surname>Di Bari</surname><given-names>S.</given-names></name>
<name><surname>Ricci</surname><given-names>P.</given-names></name>
<etal/>
</person-group><article-title>Clinical course of Coronavirus Disease-19 in patients with haematological malignancies is characterized by a longer time to respiratory deterioration compared to non-haematological ones: Results from a case&#x02013;control study</article-title><source>Infection</source><year>2022</year><volume>50</volume><fpage>1373</fpage><lpage>1382</lpage><pub-id pub-id-type="doi">10.1007/s15010-022-01869-w</pub-id><pub-id pub-id-type="pmid">35781785</pub-id>
</element-citation></ref><ref id="B6-viruses-17-00274"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Passamonti</surname><given-names>F.</given-names></name>
<name><surname>Cattaneo</surname><given-names>C.</given-names></name>
<name><surname>Arcaini</surname><given-names>L.</given-names></name>
<name><surname>Bruna</surname><given-names>R.</given-names></name>
<name><surname>Cavo</surname><given-names>M.</given-names></name>
<name><surname>Merli</surname><given-names>F.</given-names></name>
<name><surname>Angelucci</surname><given-names>E.</given-names></name>
<name><surname>Krampera</surname><given-names>M.</given-names></name>
<name><surname>Cairoli</surname><given-names>R.</given-names></name>
<name><surname>Della Porta</surname><given-names>M.G.</given-names></name>
<etal/>
</person-group><article-title>Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: A retrospective, multicentre, cohort study</article-title><source>Lancet Haematol.</source><year>2020</year><volume>7</volume><fpage>e737</fpage><lpage>e745</lpage><pub-id pub-id-type="doi">10.1016/S2352-3026(20)30251-9</pub-id><pub-id pub-id-type="pmid">32798473</pub-id>
</element-citation></ref><ref id="B7-viruses-17-00274"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zappasodi</surname><given-names>P.</given-names></name>
<name><surname>Cattaneo</surname><given-names>C.</given-names></name>
<name><surname>Ferretti</surname><given-names>V.V.</given-names></name>
<name><surname>Mina</surname><given-names>R.</given-names></name>
<name><surname>Ferreri</surname><given-names>A.J.M.</given-names></name>
<name><surname>Merli</surname><given-names>F.</given-names></name>
<name><surname>Oberti</surname><given-names>M.</given-names></name>
<name><surname>Krampera</surname><given-names>M.</given-names></name>
<name><surname>Romano</surname><given-names>A.</given-names></name>
<name><surname>Zerbi</surname><given-names>C.</given-names></name>
<etal/>
</person-group><article-title>Secondary infections worsen the outcome of COVID-19 in patients with hematological malignancies: A report from the ITA-HEMA-COV</article-title><source>Hematol. Oncol.</source><year>2022</year><volume>40</volume><fpage>846</fpage><lpage>856</lpage><pub-id pub-id-type="doi">10.1002/hon.3048</pub-id><pub-id pub-id-type="pmid">35854643</pub-id>
</element-citation></ref><ref id="B8-viruses-17-00274"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gudiol</surname><given-names>C.</given-names></name>
<name><surname>Dur&#x000e0;-Miralles</surname><given-names>X.</given-names></name>
<name><surname>Aguilar-Company</surname><given-names>J.</given-names></name>
<name><surname>Hern&#x000e1;ndez-Jim&#x000e9;nez</surname><given-names>P.</given-names></name>
<name><surname>Mart&#x000ed;nez-Cutillas</surname><given-names>M.</given-names></name>
<name><surname>Fernandez-Avil&#x000e9;s</surname><given-names>F.</given-names></name>
<name><surname>Machado</surname><given-names>M.</given-names></name>
<name><surname>V&#x000e1;zquez</surname><given-names>L.</given-names></name>
<name><surname>Mart&#x000ed;n-D&#x000e1;vila</surname><given-names>P.</given-names></name>
<name><surname>de Castro</surname><given-names>N.</given-names></name>
<etal/>
</person-group><article-title>Co-infections and superinfections complicating COVID-19 in cancer patients: A multicentre, international study</article-title><source>J. Infect.</source><year>2021</year><volume>83</volume><fpage>306</fpage><lpage>313</lpage><pub-id pub-id-type="doi">10.1016/j.jinf.2021.07.014</pub-id><pub-id pub-id-type="pmid">34302864</pub-id>
</element-citation></ref><ref id="B9-viruses-17-00274"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Alanio</surname><given-names>A.</given-names></name>
<name><surname>Delli&#x000e8;re</surname><given-names>S.</given-names></name>
<name><surname>Fodil</surname><given-names>S.</given-names></name>
<name><surname>Bretagne</surname><given-names>S.</given-names></name>
<name><surname>M&#x000e9;garbane</surname><given-names>B.</given-names></name>
</person-group><article-title>Prevalence of putative invasive pulmonary aspergillosis in critically ill patients with COVID-19</article-title><source>Lancet Respir. Med.</source><year>2020</year><volume>8</volume><fpage>e48</fpage><lpage>e49</lpage><pub-id pub-id-type="doi">10.1016/S2213-2600(20)30237-X</pub-id><pub-id pub-id-type="pmid">32445626</pub-id>
</element-citation></ref><ref id="B10-viruses-17-00274"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bartoletti</surname><given-names>M.</given-names></name>
<name><surname>Pascale</surname><given-names>R.</given-names></name>
<name><surname>Cricca</surname><given-names>M.</given-names></name>
<name><surname>Rinaldi</surname><given-names>M.</given-names></name>
<name><surname>Maccaro</surname><given-names>A.</given-names></name>
<name><surname>Bussini</surname><given-names>L.</given-names></name>
<name><surname>Fornaro</surname><given-names>G.</given-names></name>
<name><surname>Tonetti</surname><given-names>T.</given-names></name>
<name><surname>Pizzilli</surname><given-names>G.</given-names></name>
<name><surname>Francalanci</surname><given-names>E.</given-names></name>
<etal/>
</person-group><article-title>Epidemiology of Invasive Pulmonary Aspergillosis Among Intubated Patients With COVID-19: A Prospective Study</article-title><source>Clin. Infect. Dis.</source><year>2021</year><volume>73</volume><fpage>e3606</fpage><lpage>e3614</lpage><pub-id pub-id-type="doi">10.1093/cid/ciaa1065</pub-id><pub-id pub-id-type="pmid">32719848</pub-id>
</element-citation></ref><ref id="B11-viruses-17-00274"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Joseph</surname><given-names>C.</given-names></name>
<name><surname>Togawa</surname><given-names>Y.</given-names></name>
<name><surname>Shindo</surname><given-names>N.</given-names></name>
</person-group><article-title>Bacterial and viral infections associated with influenza</article-title><source>Influ. Other Respir. Viruses</source><year>2013</year><volume>7</volume><issue>(Suppl. S2)</issue><fpage>105</fpage><lpage>113</lpage><pub-id pub-id-type="doi">10.1111/irv.12089</pub-id></element-citation></ref><ref id="B12-viruses-17-00274"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cill&#x000f3;niz</surname><given-names>C.</given-names></name>
<name><surname>Ewig</surname><given-names>S.</given-names></name>
<name><surname>Men&#x000e9;ndez</surname><given-names>R.</given-names></name>
<name><surname>Ferrer</surname><given-names>M.</given-names></name>
<name><surname>Polverino</surname><given-names>E.</given-names></name>
<name><surname>Reyes</surname><given-names>S.</given-names></name>
<name><surname>Gabarr&#x000fa;s</surname><given-names>A.</given-names></name>
<name><surname>Marcos</surname><given-names>M.A.</given-names></name>
<name><surname>Cordoba</surname><given-names>J.</given-names></name>
<name><surname>Mensa</surname><given-names>J.</given-names></name>
<etal/>
</person-group><article-title>Bacterial co-infection with H1N1 infection in patients admitted with community acquired pneumonia</article-title><source>J. Infect.</source><year>2012</year><volume>65</volume><fpage>223</fpage><lpage>230</lpage><pub-id pub-id-type="doi">10.1016/j.jinf.2012.04.009</pub-id><pub-id pub-id-type="pmid">22543245</pub-id>
</element-citation></ref><ref id="B13-viruses-17-00274"><label>13.</label><element-citation publication-type="webpage"><person-group person-group-type="author">
<collab>EpiCentro</collab>
</person-group><article-title>Monitoraggio delle Varianti del Virus SARS-CoV-2 di Interesse in Sanit&#x000e0; Pubblica in Italia</article-title><year>2022</year><comment>Available online: <ext-link xlink:href="https://www.epicentro.iss.it/coronavirus/sars-cov-2-monitoraggio-varianti-indagini-rapide" ext-link-type="uri">https://www.epicentro.iss.it/coronavirus/sars-cov-2-monitoraggio-varianti-indagini-rapide</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-09-10">(accessed on 10 September 2024)</date-in-citation></element-citation></ref><ref id="B14-viruses-17-00274"><label>14.</label><element-citation publication-type="webpage"><person-group person-group-type="author">
<collab>WHO</collab>
</person-group><article-title>Clinical Care of Severe Acute Respiratory Infections</article-title><comment>Available online: <ext-link xlink:href="https://www.who.int/publications/i/item/clinical-care-of-severe-acute-respiratory-infections-tool-kit" ext-link-type="uri">https://www.who.int/publications/i/item/clinical-care-of-severe-acute-respiratory-infections-tool-kit</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-09-10">(accessed on 10 September 2024)</date-in-citation></element-citation></ref><ref id="B15-viruses-17-00274"><label>15.</label><element-citation publication-type="webpage"><person-group person-group-type="author">
<collab>ESMO</collab>
</person-group><article-title>ESMO Clinical Practice Guidelines: Haematological Malignancies</article-title><year>2022</year><comment>Available online: <ext-link xlink:href="https://www.esmo.org/guidelines/guidelines-by-topic/haematological-malignancies" ext-link-type="uri">https://www.esmo.org/guidelines/guidelines-by-topic/haematological-malignancies</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-09-10">(accessed on 10 September 2024)</date-in-citation></element-citation></ref><ref id="B16-viruses-17-00274"><label>16.</label><element-citation publication-type="gov"><article-title>CDC/NHSN Surveillance Definitions for Specific Types of Infections</article-title><comment>Available online: <ext-link xlink:href="https://www.cdc.gov/nhsn/pdfs/pscmanual/17pscnosinfdef_current.pdf" ext-link-type="uri">https://www.cdc.gov/nhsn/pdfs/pscmanual/17pscnosinfdef_current.pdf</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-09-10">(accessed on 10 September 2024)</date-in-citation></element-citation></ref><ref id="B17-viruses-17-00274"><label>17.</label><element-citation publication-type="gov"><person-group person-group-type="author">
<collab>Centers for Disease Control and Prevention Website</collab>
</person-group><article-title>National Healthcare Safety Network (NHSN). Pneumonia (Ventilator-associated [VAP] and Non-Ventilator-Associated Pneumonia [PNEU]) Event</article-title><comment>Available online: <ext-link xlink:href="https://www.cdc.gov/nhsn/pdfs/pscmanual/6pscvapcurrent.pdf" ext-link-type="uri">https://www.cdc.gov/nhsn/pdfs/pscmanual/6pscvapcurrent.pdf</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-09-10">(accessed on 10 September 2024)</date-in-citation></element-citation></ref><ref id="B18-viruses-17-00274"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Koehler</surname><given-names>P.</given-names></name>
<name><surname>Bassetti</surname><given-names>M.</given-names></name>
<name><surname>Chakrabarti</surname><given-names>A.</given-names></name>
<name><surname>Chen</surname><given-names>S.C.A.</given-names></name>
<name><surname>Colombo</surname><given-names>A.L.</given-names></name>
<name><surname>Hoenigl</surname><given-names>M.</given-names></name>
<name><surname>Klimko</surname><given-names>N.</given-names></name>
<name><surname>Lass-Fl&#x000f6;rl</surname><given-names>C.</given-names></name>
<name><surname>Oladele</surname><given-names>R.O.</given-names></name>
<name><surname>Vinh</surname><given-names>D.C.</given-names></name>
<etal/>
</person-group><article-title>Defining and managing COVID-19-associated pulmonary aspergillosis: The 2020 ECMM/ISHAM consensus criteria for research and clinical guidance</article-title><source>Lancet Infect. Dis.</source><year>2021</year><volume>21</volume><fpage>e149</fpage><lpage>e162</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(20)30847-1</pub-id><pub-id pub-id-type="pmid">33333012</pub-id>
</element-citation></ref><ref id="B19-viruses-17-00274"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>White</surname><given-names>P.L.</given-names></name>
<name><surname>Dhillon</surname><given-names>R.</given-names></name>
<name><surname>Cordey</surname><given-names>A.</given-names></name>
<name><surname>Hughes</surname><given-names>H.</given-names></name>
<name><surname>Faggian</surname><given-names>F.</given-names></name>
<name><surname>Soni</surname><given-names>S.</given-names></name>
<name><surname>Pandey</surname><given-names>M.</given-names></name>
<name><surname>Whitaker</surname><given-names>H.</given-names></name>
<name><surname>May</surname><given-names>A.</given-names></name>
<name><surname>Morgan</surname><given-names>M.</given-names></name>
<etal/>
</person-group><article-title>A National Strategy to Diagnose Coronavirus Disease 2019&#x02013;Associated Invasive Fungal Disease in the Intensive Care Unit</article-title><source>Clin. Infect. Dis.</source><year>2021</year><volume>73</volume><fpage>e1634</fpage><lpage>e1644</lpage><pub-id pub-id-type="doi">10.1093/cid/ciaa1298</pub-id><pub-id pub-id-type="pmid">32860682</pub-id>
</element-citation></ref><ref id="B20-viruses-17-00274"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Magiorakos</surname><given-names>A.P.</given-names></name>
<name><surname>Srinivasan</surname><given-names>A.</given-names></name>
<name><surname>Carey</surname><given-names>R.B.</given-names></name>
<name><surname>Carmeli</surname><given-names>Y.</given-names></name>
<name><surname>Falagas</surname><given-names>M.E.</given-names></name>
<name><surname>Giske</surname><given-names>C.G.</given-names></name>
<name><surname>Harbarth</surname><given-names>S.</given-names></name>
<name><surname>Hindler</surname><given-names>J.F.</given-names></name>
<name><surname>Kahlmeter</surname><given-names>G.</given-names></name>
<name><surname>Olsson-Liljequist</surname><given-names>B.</given-names></name>
<etal/>
</person-group><article-title>Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: An international expert proposal for interim standard definitions for acquired resistance</article-title><source>Clin. Microbiol. Infect.</source><year>2012</year><volume>18</volume><fpage>268</fpage><lpage>281</lpage><pub-id pub-id-type="doi">10.1111/j.1469-0691.2011.03570.x</pub-id><pub-id pub-id-type="pmid">21793988</pub-id>
</element-citation></ref><ref id="B21-viruses-17-00274"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ljungman</surname><given-names>P.</given-names></name>
<name><surname>Boeckh</surname><given-names>M.</given-names></name>
<name><surname>Hirsch</surname><given-names>H.H.</given-names></name>
<name><surname>Josephson</surname><given-names>F.</given-names></name>
<name><surname>Lundgren</surname><given-names>J.</given-names></name>
<name><surname>Nichols</surname><given-names>G.</given-names></name>
<name><surname>Pikis</surname><given-names>A.</given-names></name>
<name><surname>Razonable</surname><given-names>R.R.</given-names></name>
<name><surname>Miller</surname><given-names>V.</given-names></name>
<name><surname>Griffiths</surname><given-names>P.D.</given-names></name>
</person-group><article-title>Definitions of Cytomegalovirus Infection and Disease in Transplant Patients for Use in Clinical Trials</article-title><source>Clin. Infect. Dis.</source><year>2017</year><volume>64</volume><fpage>87</fpage><lpage>91</lpage><pub-id pub-id-type="doi">10.1093/cid/ciw668</pub-id><pub-id pub-id-type="pmid">27682069</pub-id>
</element-citation></ref><ref id="B22-viruses-17-00274"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Falcone</surname><given-names>M.</given-names></name>
<name><surname>Tiseo</surname><given-names>G.</given-names></name>
<name><surname>Giordano</surname><given-names>C.</given-names></name>
<name><surname>Leonildi</surname><given-names>A.</given-names></name>
<name><surname>Menichini</surname><given-names>M.</given-names></name>
<name><surname>Vecchione</surname><given-names>A.</given-names></name>
<name><surname>Pistello</surname><given-names>M.</given-names></name>
<name><surname>Guarracino</surname><given-names>F.</given-names></name>
<name><surname>Ghiadoni</surname><given-names>L.</given-names></name>
<name><surname>Forfori</surname><given-names>F.</given-names></name>
<etal/>
</person-group><article-title>Predictors of hospital-acquired bacterial and fungal superinfections in COVID-19: A prospective observational study</article-title><source>J. Antimicrob. Chemother.</source><year>2021</year><volume>76</volume><fpage>1078</fpage><lpage>1084</lpage><pub-id pub-id-type="doi">10.1093/jac/dkaa530</pub-id><pub-id pub-id-type="pmid">33374002</pub-id>
</element-citation></ref><ref id="B23-viruses-17-00274"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Smith</surname><given-names>L.</given-names></name>
<name><surname>Karaba</surname><given-names>S.M.</given-names></name>
<name><surname>Amoah</surname><given-names>J.</given-names></name>
<name><surname>Jones</surname><given-names>G.</given-names></name>
<name><surname>Avery</surname><given-names>R.K.</given-names></name>
<name><surname>Dzintars</surname><given-names>K.</given-names></name>
<name><surname>Helsel</surname><given-names>T.</given-names></name>
<name><surname>Cosgrove</surname><given-names>S.E.</given-names></name>
<name><surname>Fabre</surname><given-names>V.</given-names></name>
</person-group><article-title>Hospital-acquired infections among adult patients admitted for coronavirus disease 2019 (COVID-19)</article-title><source>Infect. Control. Hosp. Epidemiol.</source><year>2022</year><volume>43</volume><fpage>1054</fpage><lpage>1057</lpage><pub-id pub-id-type="doi">10.1017/ice.2021.148</pub-id><pub-id pub-id-type="pmid">33845927</pub-id>
</element-citation></ref><ref id="B24-viruses-17-00274"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Iacovelli</surname><given-names>A.</given-names></name>
<name><surname>Oliva</surname><given-names>A.</given-names></name>
<name><surname>Siccardi</surname><given-names>G.</given-names></name>
<name><surname>Tramontano</surname><given-names>A.</given-names></name>
<name><surname>Pellegrino</surname><given-names>D.</given-names></name>
<name><surname>Mastroianni</surname><given-names>C.M.</given-names></name>
<name><surname>Venditti</surname><given-names>M.</given-names></name>
<name><surname>Palange</surname><given-names>P.</given-names></name>
</person-group><article-title>Risk factors and effect on mortality of superinfections in a newly established COVID-19 respiratory sub-intensive care unit at University Hospital in Rome</article-title><source>BMC Pulm. Med.</source><year>2023</year><volume>23</volume><elocation-id>30</elocation-id><pub-id pub-id-type="doi">10.1186/s12890-023-02315-9</pub-id><pub-id pub-id-type="pmid">36670381</pub-id>
</element-citation></ref><ref id="B25-viruses-17-00274"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Malahe</surname><given-names>S.R.K.</given-names></name>
<name><surname>Hoek</surname><given-names>R.A.S.</given-names></name>
<name><surname>Dalm</surname><given-names>V.A.S.H.</given-names></name>
<name><surname>Broers</surname><given-names>A.E.C.</given-names></name>
<name><surname>Hoed</surname><given-names>C.M.D.</given-names></name>
<name><surname>Manintveld</surname><given-names>O.C.</given-names></name>
<name><surname>Baan</surname><given-names>C.C.</given-names></name>
<name><surname>van Deuzen</surname><given-names>C.M.</given-names></name>
<name><surname>Papageorgiou</surname><given-names>G.</given-names></name>
<name><surname>I Bax</surname><given-names>H.</given-names></name>
<etal/>
</person-group><article-title>Clinical Characteristics and Outcomes of Immunocompromised Patients With Coronavirus Disease 2019 Caused by the Omicron Variant: A Prospective, Observational Study</article-title><source>Clin. Infect. Dis.</source><year>2023</year><volume>76</volume><fpage>e172</fpage><lpage>e178</lpage><pub-id pub-id-type="doi">10.1093/cid/ciac571</pub-id><pub-id pub-id-type="pmid">35869843</pub-id>
</element-citation></ref><ref id="B26-viruses-17-00274"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nyberg</surname><given-names>T.</given-names></name>
<name><surname>Ferguson</surname><given-names>N.M.</given-names></name>
<name><surname>Nash</surname><given-names>S.G.</given-names></name>
<name><surname>Webster</surname><given-names>H.H.</given-names></name>
<name><surname>Flaxman</surname><given-names>S.</given-names></name>
<name><surname>Andrews</surname><given-names>N.</given-names></name>
<name><surname>Hinsley</surname><given-names>W.</given-names></name>
<name><surname>Bernal</surname><given-names>J.L.</given-names></name>
<name><surname>Kall</surname><given-names>M.</given-names></name>
<name><surname>Bhatt</surname><given-names>S.</given-names></name>
<etal/>
</person-group><article-title>Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: A cohort study</article-title><source>Lancet</source><year>2022</year><volume>399</volume><fpage>1303</fpage><lpage>1312</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(22)00462-7</pub-id><pub-id pub-id-type="pmid">35305296</pub-id>
</element-citation></ref><ref id="B27-viruses-17-00274"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Blennow</surname><given-names>O.</given-names></name>
<name><surname>Salmanton-Garc&#x000ed;a</surname><given-names>J.</given-names></name>
<name><surname>Nowak</surname><given-names>P.</given-names></name>
<name><surname>Itri</surname><given-names>F.</given-names></name>
<name><surname>Van Doesum</surname><given-names>J.</given-names></name>
<name><surname>L&#x000f3;pez-Garc&#x000ed;a</surname><given-names>A.</given-names></name>
<name><surname>Farina</surname><given-names>F.</given-names></name>
<name><surname>Jaksic</surname><given-names>O.</given-names></name>
<name><surname>Pincz&#x000e9;s</surname><given-names>L.I.</given-names></name>
<name><surname>Bilgin</surname><given-names>Y.M.</given-names></name>
<etal/>
</person-group><article-title>Outcome of infection with omicron SARS-CoV-2 variant in patients with hematological malignancies: An EPICOVIDEHA survey report</article-title><source>Am. J. Hematol.</source><year>2022</year><volume>97</volume><fpage>E312</fpage><lpage>E317</lpage><pub-id pub-id-type="doi">10.1002/ajh.26626</pub-id><pub-id pub-id-type="pmid">35702878</pub-id>
</element-citation></ref><ref id="B28-viruses-17-00274"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Montassier</surname><given-names>E.</given-names></name>
<name><surname>Batard</surname><given-names>E.</given-names></name>
<name><surname>Gastinne</surname><given-names>T.</given-names></name>
<name><surname>Potel</surname><given-names>G.</given-names></name>
<name><surname>De La Cocheti&#x000e8;re</surname><given-names>M.F.</given-names></name>
</person-group><article-title>Recent changes in bacteremia in patients with cancer: A systematic review of epidemiology and antibiotic resistance</article-title><source>Eur. J. Clin. Microbiol. Infect Dis.</source><year>2013</year><volume>32</volume><fpage>841</fpage><lpage>850</lpage><pub-id pub-id-type="doi">10.1007/s10096-013-1819-7</pub-id><pub-id pub-id-type="pmid">23354675</pub-id>
</element-citation></ref><ref id="B29-viruses-17-00274"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Iacovelli</surname><given-names>A.</given-names></name>
<name><surname>Oliva</surname><given-names>A.</given-names></name>
<name><surname>Mirabelli</surname><given-names>F.M.</given-names></name>
<name><surname>Giannone</surname><given-names>S.</given-names></name>
<name><surname>Laguardia</surname><given-names>M.</given-names></name>
<name><surname>Morviducci</surname><given-names>M.</given-names></name>
<name><surname>Nicolardi</surname><given-names>M.L.</given-names></name>
<name><surname>Repaci</surname><given-names>E.</given-names></name>
<name><surname>Sanzari</surname><given-names>M.T.</given-names></name>
<name><surname>Leanza</surname><given-names>C.</given-names></name>
<etal/>
</person-group><article-title>Risk factors for COVID-19 associated pulmonary aspergillosis and outcomes in patients with acute respiratory failure in a respiratory sub-intensive care unit</article-title><source>BMC Infect. Dis.</source><year>2024</year><volume>24</volume><elocation-id>392</elocation-id><pub-id pub-id-type="doi">10.1186/s12879-024-09283-3</pub-id><pub-id pub-id-type="pmid">38605300</pub-id>
</element-citation></ref><ref id="B30-viruses-17-00274"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Saade</surname><given-names>A.</given-names></name>
<name><surname>Moratelli</surname><given-names>G.</given-names></name>
<name><surname>Azoulay</surname><given-names>E.</given-names></name>
<name><surname>Darmon</surname><given-names>M.</given-names></name>
</person-group><article-title>Herpesvirus reactivation during severe COVID-19 and high rate of immune defect</article-title><source>Infect. Dis. Now</source><year>2021</year><volume>51</volume><fpage>676</fpage><lpage>679</lpage><pub-id pub-id-type="doi">10.1016/j.idnow.2021.07.005</pub-id><pub-id pub-id-type="pmid">34332165</pub-id>
</element-citation></ref><ref id="B31-viruses-17-00274"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Simonnet</surname><given-names>A.</given-names></name>
<name><surname>Engelmann</surname><given-names>I.</given-names></name>
<name><surname>Moreau</surname><given-names>A.-S.</given-names></name>
<name><surname>Garcia</surname><given-names>B.</given-names></name>
<name><surname>Six</surname><given-names>S.</given-names></name>
<name><surname>El Kalioubie</surname><given-names>A.</given-names></name>
<name><surname>Robriquet</surname><given-names>L.</given-names></name>
<name><surname>Hober</surname><given-names>D.</given-names></name>
<name><surname>Jourdain</surname><given-names>M.</given-names></name>
</person-group><article-title>High incidence of Epstein&#x02013;Barr virus, cytomegalovirus, and human-herpes virus-6 reactivations in critically ill patients with COVID-19</article-title><source>Infect. Dis. Now</source><year>2021</year><volume>51</volume><fpage>296</fpage><lpage>299</lpage><pub-id pub-id-type="doi">10.1016/j.idnow.2021.01.005</pub-id><pub-id pub-id-type="pmid">33495765</pub-id>
</element-citation></ref></ref-list></back><floats-group><table-wrap position="float" id="viruses-17-00274-t001"><object-id pub-id-type="pii">viruses-17-00274-t001_Table 1</object-id><label>Table 1</label><caption><p>Demographic and clinical features of 217 patients enrolled. All results are reported as median and interquartile range (IQR) or absolute frequency and percentage.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Variable</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Value</th></tr></thead><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">Age, median (IQR)</td><td align="center" valign="middle" rowspan="1" colspan="1">69 (57&#x02013;77)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Male/Female, n (%)</td><td align="center" valign="middle" rowspan="1" colspan="1">134 (61.7)/83 (38.2)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Systemic arterial hypertension, n (%)</td><td align="center" valign="middle" rowspan="1" colspan="1">96 (44)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Cardiovascular disease, n (%)</td><td align="center" valign="middle" rowspan="1" colspan="1">37 (17)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Diabetes mellitus, n (%)</td><td align="center" valign="middle" rowspan="1" colspan="1">29 (13.4)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">COPD, n (%)</td><td align="center" valign="middle" rowspan="1" colspan="1">20 (9.2)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Omicron variant, n (%)</td><td align="center" valign="middle" rowspan="1" colspan="1">111 (51.1)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Vaccination, n (%)</td><td align="center" valign="middle" rowspan="1" colspan="1">139 (64)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Asymptomatic COVID-19, n (%)</td><td align="center" valign="middle" rowspan="1" colspan="1">40 (18.4)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Severe COVID-19, n (%)</td><td align="center" valign="middle" rowspan="1" colspan="1">46 (21.2)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">eGFR, ml/min, median (IQR)</td><td align="center" valign="middle" rowspan="1" colspan="1">79.7 (58.8&#x02013;96.5)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">eGFR &#x02264; 45 mL/min, n (%)</td><td align="center" valign="middle" rowspan="1" colspan="1">34 (15.7)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Neutropenia, n (%)</td><td align="center" valign="middle" rowspan="1" colspan="1">23 (10.6)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Hematological disease, n (%)</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x02003;ALL</td><td align="center" valign="middle" rowspan="1" colspan="1">10 (4.6)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x02003;AML</td><td align="center" valign="middle" rowspan="1" colspan="1">22 (10.1)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x02003;CML</td><td align="center" valign="middle" rowspan="1" colspan="1">7 (3.2)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x02003;CLL</td><td align="center" valign="middle" rowspan="1" colspan="1">23 (10.6)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x02003;PLL</td><td align="center" valign="middle" rowspan="1" colspan="1">2 (0.9)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x02003;PL</td><td align="center" valign="middle" rowspan="1" colspan="1">1 (0.5)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x02003;MM</td><td align="center" valign="middle" rowspan="1" colspan="1">23 (10.6)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x02003;MS</td><td align="center" valign="middle" rowspan="1" colspan="1">17 (7.8)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x02003;Myelofibrosis</td><td align="center" valign="middle" rowspan="1" colspan="1">9 (4.1)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x02003;NHL</td><td align="center" valign="middle" rowspan="1" colspan="1">84 (38.7)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x02003;HL</td><td align="center" valign="middle" rowspan="1" colspan="1">8 (3.7)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x02003;Others</td><td align="center" valign="middle" rowspan="1" colspan="1">11 (5.1)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Remission of hematological disease, n (%)</td><td align="center" valign="middle" rowspan="1" colspan="1">97 (44.7)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Chronic steroid therapy, n (%)</td><td align="center" valign="middle" rowspan="1" colspan="1">75 (34.6)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Active treatment, n (%)</td><td align="center" valign="middle" rowspan="1" colspan="1">118 (54.4)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">MDR colonization, n (%)</td><td align="center" valign="middle" rowspan="1" colspan="1">41 (18.9)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Secondary infection, n (%)</td><td align="center" valign="middle" rowspan="1" colspan="1">96 (44.2)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x02003;BSI &#x000b0;</td><td align="center" valign="middle" rowspan="1" colspan="1">41 (42.7)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x02003;Pneumonia *</td><td align="center" valign="middle" rowspan="1" colspan="1">29 (30.5)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x02003;UTI</td><td align="center" valign="middle" rowspan="1" colspan="1">15 (14.7)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x02003;Intra-abdominal</td><td align="center" valign="middle" rowspan="1" colspan="1">6 (6.3)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x02003;Others <sup>&#x02020;</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">4 (4.2)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Viral reactivation <sup>&#x000a7;</sup>, n (%)</td><td align="center" valign="middle" rowspan="1" colspan="1">20 (9.2)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Exitus</td><td align="center" valign="middle" rowspan="1" colspan="1">63 (29)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Length of stay, days</td><td align="center" valign="middle" rowspan="1" colspan="1">16 (9&#x02013;30)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Admission to ICU, n (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">31 (14.3)</td></tr></tbody></table><table-wrap-foot><fn><p>&#x000b0; <italic toggle="yes">E. faecium</italic> (19%), <italic toggle="yes">S. epidermidis</italic> (14.3%), <italic toggle="yes">K. pneumoniae</italic> (14.3%), <italic toggle="yes">E. coli</italic> (14.3%), <italic toggle="yes">S. haemolyticus</italic> (14.3%), and <italic toggle="yes">A. baumannii</italic> (12%). * HAP/VAP 17 (58.6%), CAPA 12 (41.4%), HAP/VAP mainly caused by <italic toggle="yes">A. baumannii</italic> (18.6%) and <italic toggle="yes">K. pneumoniae</italic> (14%). <sup>&#x02020;</sup> 2 patients with skin and soft tissue infection, 1 patient with <italic toggle="yes">S. aureus</italic> otomastoiditis, and 1 patient with mucormycosis. <sup>&#x000a7;</sup> CMV 15 (78.9%), other Herpesviruses 4 (21%). ALL: acute lymphocytic leukaemia, AML: acute myeloid leukaemia, CML: chronic myeloid leukaemia, CLL: chronic lymphocytic leukaemia, PLL: prolymphocytic leukemia, PL: plasma cell leukemia, MM: multiple myeloma; MS: myelodysplastic syndrome, NHL: non-Hodgkin lymphoma, HL: Hodgkin lymphoma, ICU: Intensive Care Unit, eGFR: estimated glomerular filtration rate, CRP: C-reactive protein, COPD: chronic obstructive pulmonary disease. BSI: bloodstream infections, MDR: multidrug-resistant, UTI: urinary tract infections, HAP: hospital-acquired pneumonia, VAP: ventilator-associated pneumonia, CAPA: COVID-19 associated pulmonary aspergillosis.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="viruses-17-00274-t002"><object-id pub-id-type="pii">viruses-17-00274-t002_Table 2</object-id><label>Table 2</label><caption><p>Comparative analysis of 217 patients enrolled, grouped according to exitus or development of secondary infections. All results are reported as median and interquartile range (IQR) or absolute frequency and percentage. Mann&#x02013;Whitney U tests were used to compare variables where medians are reported and a Chi-square or Fisher&#x02019;s exact test was used to compare variables where frequencies are reported.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Variables</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Exitus <break/>(n = 63)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">No Exitus <break/>(n = 154)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>
</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Secondary Infection<break/>(n = 96)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">No Secondary Infection<break/>(n = 121)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>
</th></tr></thead><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">Age, median (IQR)</td><td align="center" valign="middle" rowspan="1" colspan="1">70 (61.5&#x02013;79)</td><td align="center" valign="middle" rowspan="1" colspan="1">69 (55&#x02013;76.5)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003e;0.05</td><td align="center" valign="middle" rowspan="1" colspan="1">69.5 (59.7&#x02013;78)</td><td align="center" valign="middle" rowspan="1" colspan="1">69 (53&#x02013;77)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003e;0.05</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Gender male, n (%)</td><td align="center" valign="middle" rowspan="1" colspan="1">91 (59.1)</td><td align="center" valign="middle" rowspan="1" colspan="1">43 (68.2)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003e;0.05</td><td align="center" valign="middle" rowspan="1" colspan="1">65 (67.7)</td><td align="center" valign="middle" rowspan="1" colspan="1">69 (57)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003e;0.05</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Systemic arterial hypertension, n (%)</td><td align="center" valign="middle" rowspan="1" colspan="1">29 (46)</td><td align="center" valign="middle" rowspan="1" colspan="1">67 (43.5)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003e;0.05</td><td align="center" valign="middle" rowspan="1" colspan="1">41 (42.7)</td><td align="center" valign="middle" rowspan="1" colspan="1">55 (45.4)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003e;0.05</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Cardiovascular diseases, n (%)</td><td align="center" valign="middle" rowspan="1" colspan="1">9 (14.3)</td><td align="center" valign="middle" rowspan="1" colspan="1">28 (18.2)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003e;0.05</td><td align="center" valign="middle" rowspan="1" colspan="1">16 (16.7)</td><td align="center" valign="middle" rowspan="1" colspan="1">21 (17.3)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003e;0.05</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Diabetes mellitus, n (%)</td><td align="center" valign="middle" rowspan="1" colspan="1">6 (9.5)</td><td align="center" valign="middle" rowspan="1" colspan="1">23 (14.9)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003e;0.05</td><td align="center" valign="middle" rowspan="1" colspan="1">11 (11.4)</td><td align="center" valign="middle" rowspan="1" colspan="1">18 (14.9)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003e;0.05</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">COPD, n (%)</td><td align="center" valign="middle" rowspan="1" colspan="1">8 (12.7)</td><td align="center" valign="middle" rowspan="1" colspan="1">12 (7.8)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003e;0.05</td><td align="center" valign="middle" rowspan="1" colspan="1">9 (9.4)</td><td align="center" valign="middle" rowspan="1" colspan="1">11 (9.1)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003e;0.05</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Omicron variant, n (%)</td><td align="center" valign="middle" rowspan="1" colspan="1">24 (38.1)</td><td align="center" valign="middle" rowspan="1" colspan="1">87 (56.5)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c;0.01</td><td align="center" valign="middle" rowspan="1" colspan="1">54 (56.2)</td><td align="center" valign="middle" rowspan="1" colspan="1">57 (47.1)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003e;0.05</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Vaccination, n (%)</td><td align="center" valign="middle" rowspan="1" colspan="1">36 (57.1)</td><td align="center" valign="middle" rowspan="1" colspan="1">103 (67.3)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003e;0.05</td><td align="center" valign="middle" rowspan="1" colspan="1">66 (68.7)</td><td align="center" valign="middle" rowspan="1" colspan="1">73 (60.8)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003e;0.05</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Asymptomatic COVID-19, n (%)</td><td align="center" valign="middle" rowspan="1" colspan="1">8 (12.7)</td><td align="center" valign="middle" rowspan="1" colspan="1">32 (20.8)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003e;0.05</td><td align="center" valign="middle" rowspan="1" colspan="1">21 (21.9)</td><td align="center" valign="middle" rowspan="1" colspan="1">19 (15.7)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003e;0.05</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Severe COVID-19, n (%)</td><td align="center" valign="middle" rowspan="1" colspan="1">29 (46)</td><td align="center" valign="middle" rowspan="1" colspan="1">17 (11)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="center" valign="middle" rowspan="1" colspan="1">29 (30.2)</td><td align="center" valign="middle" rowspan="1" colspan="1">17 (14)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c;0.01</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">eGFR, ml/min, median (IQR)</td><td align="center" valign="middle" rowspan="1" colspan="1">75.3 (49.9&#x02013;95.2)</td><td align="center" valign="middle" rowspan="1" colspan="1">81.6 (61.9&#x02013;96.9)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003e;0.05</td><td align="center" valign="middle" rowspan="1" colspan="1">77.7 (57.2&#x02013;94.7)</td><td align="center" valign="middle" rowspan="1" colspan="1">81.6 (61.2&#x02013;100.6)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003e;0.05</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">eGFR &#x02264; 45 mL/min, n (%)</td><td align="center" valign="middle" rowspan="1" colspan="1">20 (31.7)</td><td align="center" valign="middle" rowspan="1" colspan="1">14 (9.1)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="center" valign="middle" rowspan="1" colspan="1">19 (19.8)</td><td align="center" valign="middle" rowspan="1" colspan="1">15 (12.4)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003e;0.05</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">CRP/albumin, median (IQR)</td><td align="center" valign="middle" rowspan="1" colspan="1">2 (0.9&#x02013;4.9)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.7 (0.3&#x02013;1.9)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="center" valign="middle" rowspan="1" colspan="1">1.7 (0.6&#x02013;3.6)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.7 (0.2&#x02013;1.6)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">D-Dimer, ng/mL, median (IQR)</td><td align="center" valign="middle" rowspan="1" colspan="1">1162.5 (798.5&#x02013;2473)</td><td align="center" valign="middle" rowspan="1" colspan="1">729.5 (415&#x02013;1554)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="center" valign="middle" rowspan="1" colspan="1">1156 (632.5&#x02013;2665)</td><td align="center" valign="middle" rowspan="1" colspan="1">736 (415&#x02013;1424.2)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c;0.01</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Neutropenia, n (%)</td><td align="center" valign="middle" rowspan="1" colspan="1">10 (15.9)</td><td align="center" valign="middle" rowspan="1" colspan="1">13 (8.5)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003e;0.05</td><td align="center" valign="middle" rowspan="1" colspan="1">15 (15.6)</td><td align="center" valign="middle" rowspan="1" colspan="1">8 (6.7)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c;0.05</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Hematological disease, n (%)</td><td align="center" valign="middle" rowspan="1" colspan="1">1 (1.6)</td><td align="center" valign="middle" rowspan="1" colspan="1">9 (5.8)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003e;0.05</td><td align="center" valign="middle" rowspan="1" colspan="1">5 (5.2)</td><td align="center" valign="middle" rowspan="1" colspan="1">5 (4.1)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003e;0.05</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x02003;ALL</td><td align="center" valign="middle" rowspan="1" colspan="1">8 (12.7)</td><td align="center" valign="middle" rowspan="1" colspan="1">14 (9.1)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003e;0.05</td><td align="center" valign="middle" rowspan="1" colspan="1">13 (13.5)</td><td align="center" valign="middle" rowspan="1" colspan="1">9 (7.4)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003e;0.05</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x02003;AML</td><td align="center" valign="middle" rowspan="1" colspan="1">1 (1.6)</td><td align="center" valign="middle" rowspan="1" colspan="1">6 (3.9)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003e;0.05</td><td align="center" valign="middle" rowspan="1" colspan="1">2 (2.1)</td><td align="center" valign="middle" rowspan="1" colspan="1">5 (4.1)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003e;0.05</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x02003;CML</td><td align="center" valign="middle" rowspan="1" colspan="1">7 (11.1)</td><td align="center" valign="middle" rowspan="1" colspan="1">16 (10.4)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003e;0.05</td><td align="center" valign="middle" rowspan="1" colspan="1">11 (11.4)</td><td align="center" valign="middle" rowspan="1" colspan="1">12 (9.9)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003e;0.05</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x02003;CLL</td><td align="center" valign="middle" rowspan="1" colspan="1">0 (0)</td><td align="center" valign="middle" rowspan="1" colspan="1">2 (1.3)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003e;0.05</td><td align="center" valign="middle" rowspan="1" colspan="1">1 (1)</td><td align="center" valign="middle" rowspan="1" colspan="1">1 (0.8)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003e;0.05</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x02003;PLL</td><td align="center" valign="middle" rowspan="1" colspan="1">1 (1.6)</td><td align="center" valign="middle" rowspan="1" colspan="1">0 (0)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003e;0.05</td><td align="center" valign="middle" rowspan="1" colspan="1">0 (0)</td><td align="center" valign="middle" rowspan="1" colspan="1">1 (0.8)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003e;0.05</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x02003;PL</td><td align="center" valign="middle" rowspan="1" colspan="1">7 (11.1)</td><td align="center" valign="middle" rowspan="1" colspan="1">16 (10.4)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003e;0.05</td><td align="center" valign="middle" rowspan="1" colspan="1">9 (9.4)</td><td align="center" valign="middle" rowspan="1" colspan="1">14 (11.6)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003e;0.05</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x02003;MM</td><td align="center" valign="middle" rowspan="1" colspan="1">3 (4.7)</td><td align="center" valign="middle" rowspan="1" colspan="1">14 (9.1)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003e;0.05</td><td align="center" valign="middle" rowspan="1" colspan="1">9 (9.4)</td><td align="center" valign="middle" rowspan="1" colspan="1">8 (6.6)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003e;0.05</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x02003;MS</td><td align="center" valign="middle" rowspan="1" colspan="1">2 (3.2)</td><td align="center" valign="middle" rowspan="1" colspan="1">7 (4.5)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003e;0.05</td><td align="center" valign="middle" rowspan="1" colspan="1">2 (2.1)</td><td align="center" valign="middle" rowspan="1" colspan="1">7 (5.8)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003e;0.05</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x02003;Myelofibrosis</td><td align="center" valign="middle" rowspan="1" colspan="1">30 (47.6)</td><td align="center" valign="middle" rowspan="1" colspan="1">54 (35.1)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003e;0.05</td><td align="center" valign="middle" rowspan="1" colspan="1">37 (38.5)</td><td align="center" valign="middle" rowspan="1" colspan="1">47 (38.8)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003e;0.05</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x02003;NHL</td><td align="center" valign="middle" rowspan="1" colspan="1">3 (4.8)</td><td align="center" valign="middle" rowspan="1" colspan="1">5 (3.3)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003e;0.05</td><td align="center" valign="middle" rowspan="1" colspan="1">3 (3.1)</td><td align="center" valign="middle" rowspan="1" colspan="1">5 (4.1)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003e;0.05</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x02003;HL</td><td align="center" valign="middle" rowspan="1" colspan="1">0 (0)</td><td align="center" valign="middle" rowspan="1" colspan="1">2 (1.3)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003e;0.05</td><td align="center" valign="middle" rowspan="1" colspan="1">1 (1)</td><td align="center" valign="middle" rowspan="1" colspan="1">1 (0.8)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003e;0.05</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x02003;Others</td><td align="center" valign="middle" rowspan="1" colspan="1">0 (0)</td><td align="center" valign="middle" rowspan="1" colspan="1">1 (0.7)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003e;0.05</td><td align="center" valign="middle" rowspan="1" colspan="1">1 (1.3)</td><td align="center" valign="middle" rowspan="1" colspan="1">0 (0)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003e;0.05</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Remission of hematological disease, n (%)</td><td align="center" valign="middle" rowspan="1" colspan="1">21 (33.3)</td><td align="center" valign="middle" rowspan="1" colspan="1">76 (49.3)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c;0.05</td><td align="center" valign="middle" rowspan="1" colspan="1">41 (42.7)</td><td align="center" valign="middle" rowspan="1" colspan="1">56 (46.3)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003e;0.05</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Chronic steroid therapy, n (%)</td><td align="center" valign="middle" rowspan="1" colspan="1">31 (50)</td><td align="center" valign="middle" rowspan="1" colspan="1">44 (28.8)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c;0.01</td><td align="center" valign="middle" rowspan="1" colspan="1">46 (48.4)</td><td align="center" valign="middle" rowspan="1" colspan="1">29 (24.2)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Active treatment, n (%)</td><td align="center" valign="middle" rowspan="1" colspan="1">32 (50.8)</td><td align="center" valign="middle" rowspan="1" colspan="1">86 (55.8)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003e;0.05</td><td align="center" valign="middle" rowspan="1" colspan="1">52 (54.2)</td><td align="center" valign="middle" rowspan="1" colspan="1">66 (54.5)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003e;0.05</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Length of stay, days median (IQR)</td><td align="center" valign="middle" rowspan="1" colspan="1">20 (10.5&#x02013;30)</td><td align="center" valign="middle" rowspan="1" colspan="1">16 (9&#x02013;30)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003e;0.05</td><td align="center" valign="middle" rowspan="1" colspan="1">30 (14.7&#x02013;30)</td><td align="center" valign="middle" rowspan="1" colspan="1">11 (7&#x02013;21)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Admission to ICU, n (%)</td><td align="center" valign="middle" rowspan="1" colspan="1">26 (41.3)</td><td align="center" valign="middle" rowspan="1" colspan="1">5 (3.2)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="center" valign="middle" rowspan="1" colspan="1">22 (71)</td><td align="center" valign="middle" rowspan="1" colspan="1">9 (29)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">MDR colonization, n (%)</td><td align="center" valign="middle" rowspan="1" colspan="1">23 (36.5)</td><td align="center" valign="middle" rowspan="1" colspan="1">18 (11.7)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="center" valign="middle" rowspan="1" colspan="1">34 (35.4)</td><td align="center" valign="middle" rowspan="1" colspan="1">7 (5.8)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Secondary infectious disease, n (%)</td><td align="center" valign="middle" rowspan="1" colspan="1">45 (71.4)</td><td align="center" valign="middle" rowspan="1" colspan="1">50 (32.4)</td><td rowspan="6" align="center" valign="middle" colspan="1">&#x0003c;0.001</td><td rowspan="6" align="center" valign="middle" colspan="1">NA</td><td rowspan="6" align="center" valign="middle" colspan="1">NA</td><td rowspan="6" align="center" valign="middle" colspan="1">NA</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x02003;Bloodstream infection</td><td align="center" valign="middle" rowspan="1" colspan="1">26 (41.3)</td><td align="center" valign="middle" rowspan="1" colspan="1">15 (9.7)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x02003;Respiratory infection *</td><td align="center" valign="middle" rowspan="1" colspan="1">10 (15.9)</td><td align="center" valign="middle" rowspan="1" colspan="1">19 (12.3)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x02003;Urinary tract infection</td><td align="center" valign="middle" rowspan="1" colspan="1">4 (6.3)</td><td align="center" valign="middle" rowspan="1" colspan="1">11 (7.1)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x02003;Intra-abdominal</td><td align="center" valign="middle" rowspan="1" colspan="1">4 (6.3)</td><td align="center" valign="middle" rowspan="1" colspan="1">2 (1.3)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x02003;Others</td><td align="center" valign="middle" rowspan="1" colspan="1">0 (0)</td><td align="center" valign="middle" rowspan="1" colspan="1">3 (1.9)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Viral reactivation, n (%)</td><td align="center" valign="middle" rowspan="1" colspan="1">12 (19)</td><td align="center" valign="middle" rowspan="1" colspan="1">8 (5.2)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="center" valign="middle" rowspan="1" colspan="1">NA</td><td align="center" valign="middle" rowspan="1" colspan="1">NA</td><td align="center" valign="middle" rowspan="1" colspan="1">NA</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Exitus, n (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">45 (47.36)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">18 (14.7)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003c;0.01</td></tr></tbody></table><table-wrap-foot><fn><p>* including HAP/VAP and CAPA. ALL: acute lymphocytic leukemia, AML: acute myeloid leukemia, CML: chronic myeloid leukemia, CLL: chronic lymphocytic leukemia, PLL: prolymphocytic leukemia, PL: plasma cell leukemia, MM: multiple myeloma; MS: myelodysplastic syndrome, NHL: non-Hodgkin lymphoma, HL: Hodgkin lymphoma, ICU: Intensive Care Unit, eGFR: estimated glomerular filtration rate, CRP: C-reactive protein, COPD: chronic obstructive pulmonary disease, MDR: multidrug-resistant, UTI: urinary tract infection, HAP: hospital-acquired pneumonia, VAP: ventilator-associated pneumonia, CAPA: COVID-19-associated pulmonary aspergillosis.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="viruses-17-00274-t003"><object-id pub-id-type="pii">viruses-17-00274-t003_Table 3</object-id><label>Table 3</label><caption><p>Multivariable logistic regression analysis with odds (OR) and 95% confidence interval (CI) for exitus and secondary infections.</p></caption><table frame="hsides" rules="groups"><tbody><tr><td colspan="3" align="center" valign="middle" style="border-top:solid thin" rowspan="1">
<bold>Dependent Variable: Exitus</bold>
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Independent Variables</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>OR (95% CI)</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>
<italic toggle="yes">p</italic>
</bold>
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Age</td><td align="center" valign="middle" rowspan="1" colspan="1">1.010 (0.977; 1.044)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003e;0.05</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Female Sex</td><td align="center" valign="middle" rowspan="1" colspan="1">0.901 (0.325; 2.494)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003e;0.05</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Omicron</td><td align="center" valign="middle" rowspan="1" colspan="1">0.707 (0.260; 1.917)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003e;0.05</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Severe COVID-19</td><td align="center" valign="middle" rowspan="1" colspan="1">8.229 (2.913; 23.249)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Chronic steroid therapy</td><td align="center" valign="middle" rowspan="1" colspan="1">2.803 (1.003; 7.830)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c;0.05</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Remission</td><td align="center" valign="middle" rowspan="1" colspan="1">0.488 (0.183; 1.306)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003e;0.05</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">eGFR &#x02264; 45 mL/min</td><td align="center" valign="middle" rowspan="1" colspan="1">11.338 (3.273; 39.278)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">CRP/albumin</td><td align="center" valign="middle" rowspan="1" colspan="1">1 (0.993; 1.006)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003e;0.05</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Admission to ICU</td><td align="center" valign="middle" rowspan="1" colspan="1">15.232 (3.838; 60.452)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Secondary infections</td><td align="center" valign="middle" rowspan="1" colspan="1">2.892 (1.093; 7.649)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c;0.05</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Viral reactivation</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6.269 (1.734; 22.669)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003c;0.01</td></tr><tr><td colspan="3" align="center" valign="middle" rowspan="1">
<bold>Dependent Variable: Secondary Infections</bold>
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Variables</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>OR (95% CI)</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>
<italic toggle="yes">p</italic>
</bold>
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Age</td><td align="center" valign="middle" rowspan="1" colspan="1">1.007 (0.983; 1.032)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003e;0.05</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Female sex</td><td align="center" valign="middle" rowspan="1" colspan="1">0.697 (0.331; 1.468)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003e;0.05</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Severe COVID-19 </td><td align="center" valign="middle" rowspan="1" colspan="1">2.957 (1.258; 6.950)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c;0.05</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Chronic steroid therapy</td><td align="center" valign="middle" rowspan="1" colspan="1">2.902 (1.421; 5.925)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c;0.01</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Neutropenia</td><td align="center" valign="middle" rowspan="1" colspan="1">3.280 (1.067; 10.087)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c;0.05</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">CRP/albumin</td><td align="center" valign="middle" rowspan="1" colspan="1">0.999 (0.989; 1.009)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003e;0.05</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Admission to ICU</td><td align="center" valign="middle" rowspan="1" colspan="1">1.221 (0.444; 3.359)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003e;0.05</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Length of stay</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.095 (1.056; 1.136)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003c;0.001</td></tr></tbody></table><table-wrap-foot><fn><p>ICU: Intensive Care Unit, eGFR: estimated glomerular filtration rate, CRP: C-reactive protein.</p></fn></table-wrap-foot></table-wrap></floats-group></article>